Ikon Pass Launches the 25/26 Winter Season as Arapahoe Basin Opens First in North America Colorado, October 26, 2025 — Winter has officially arrived for Ikon Pass holders around the world. At precisely 8:30 a.m. MST today, Arapahoe Basin in…
Rosen Law Firm Alerts Dow Inc. (NYSE: DOW) Investors to Class Action Lawsuit and Encourages Shareholders to Contact the Firm Regarding Their Rights Rosen Law Firm, a global investor rights law firm, announces that a shareholder has filed a class…
Hyundai Translead to Become Official Distributor of Hyundai’s XCIENT Fuel Cell Trucks in North America In a strategic move that underscores Hyundai’s accelerating commitment to zero-emission commercial mobility, Hyundai Translead has been appointed as the official distributor of Hyundai Motor…
Ferrer Completes Patient Enrollment for the PROSPER Phase II Clinical Trial in Progressive Supranuclear Palsy Ahead of Schedule Barcelona, Spain — [October 2025] — Ferrer, the international pharmaceutical company headquartered in Spain, today announced the successful completion of patient recruitment…
the world’s leading quantum company, today announced its role as a founding member of Q-Alliance, an ambitious new initiative to establish a world-class quantum computing hub in Lombardy, Italy. Formed in alignment with Italy’s National Strategy for Quantum Technologies, Q-Alliance…
a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at IDWeek 2025™ in Atlanta, Ga., by researchers from Columbia University Irving Medical Center show metagenomic sequencing that detects both RNA and DNA pathogens, available through Delve…
Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced clinical data for IAM1363, a brain-penetrant HER2 small-molecule tyrosine kinase inhibitor (TKI), which showed anti-tumor activity in heavily pretreated…
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced the appointment of Thomas Fuchs as CEO. Thomas will lead the Company to advance its pipeline of proprietary drug…
announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma…
For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a life-threatening allergic reaction.1,2 Yet from today, the UK’s first needle-free emergency anaphylaxis treatment, the EURneffy® nasal adrenaline spray, is available on prescription.3 EURneffy® 2 mg nasal spray offers a…